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1. Introduction 
Oxygen transport is a primary goal of erythrocytes. The high maintenance of oxygen in 
erythrocytes defines high speed of formation of active forms of oxygen – superoxide (O2⎯), a 
hydrogen peroxide (H2O2) and a hydroxyl radical (·OH). A constant source of active forms 
of oxygen in erythrocytes is hemoglobin oxidation in a methemoglobin with formation of 
superoxide (O2⎯). Therefore erythrocytes should have a powerful antioxidant system, which 
prevents the toxic action of active forms of oxygen on hemoglobin and erythrocyte 
membrane. Mature erythrocytes have neither cytoplasmic organelles nor a nucleus and 
consequently are not capable to synthesize proteins and lipids, to carry out oxidative 
phosphorylation or to maintain tricarboxylic acid cycle reactions. The energy of erythrocytes 
comes for the most part from anaerobic glycolysis – via the Embden-Meyerhof-Parnas 
pathway (EMP pathway). Thus, glucose catabolism provides preservation of structure and 
function of hemoglobin, integrity of an erythrocyte membrane and formation of energy for 
the work of ionic pumps. Anaerobic glycolysis in itself is a power-consuming process. 
Glucose arrives in erythrocytes by the facilitated diffusion by glucose transporter type 1. 
Hexokinase is the first enzyme of EMP pathway, it provides glucose phosphorylation. 
Further during consecutive reactions with participation of glucose-6-phosphate isomerase, 
phosphofructokinase, aldolase, glyceraldehydes 3-phosphate dehydrogenase, 
phosphoglycerate kinase, phosphoglycerate mutase, enolase, pyruvate kinase  one molecule 
of glucose gives 4 molecules of  adenosine triphosphate (ATP) and 2 molecules of restored 
nicotinamide adenine dinucleotide (NADH), and at the same time, 2 ATP  molecules are 
spent at the initial stage of EMP pathway. A certain quantity of glucose with formation of 
restored compounds – glutathione (GSH) and nicotinamide adenine dinucleotide phosphate 
(NADPH) is taken away through pentose phosphate pathway (aerobic glycolysis). Glucose-
6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase provide the stages of 
pentose phosphate pathway. The hydroxyl radical, the most active component of oxidative 
stress, is neutralized by GSH. Methemoglobin reductase restores a methemoglobin into 
hemoglobin, NADPH being the donor of hydrogen, which is formed in EMP pathway and 
NADPH is in its turn formed in pentose phosphate pathway. Superoxide dismutase 1 
enzyme contributes superoxide (O2⎯) to turn into hydrogen peroxide. The hydrogen 
peroxide is destroyed by catalase and glutathione peroxidase, GSH being the donor of 
hydrogen. Peroxiredoxin 2 is an antioxidant enzyme that uses cystein residues to 
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decompose peroxides. Peroxiredoxin 2 is the third most abundant protein in erythrocytes, 
and competes effectively with catalase and glutathione peroxidase to scavenge low levels of 
hydrogen peroxide, including that derived from hemoglobin autoxidation. GSH reductase 
restores oxidized GSH at the expense of NADPH energy. The final step in GSH synthesis is 
catalysed by the glutathione synthetase. Thus, resistance of erythrocytes to oxidative stress 
will depend on the activity of glucose transporter type 1, glycolysis enzymes, glutathione 
synthetase, glutathione reductase, glutathione peroxidase, peroxiredoxin 2, superoxide 
dismutase 1, catalase and nucleotide metabolism. Activation of oxidative stress occurs in 
case of infection, hypoxic ischemia, acidosis, effect of some medications and toxins. Low 
resistance of erythrocytes to oxidative stress leads to hemoglobin precipitation and 
erythrocytes hemolysis. Thus, erythrocytes become sources of active forms of oxygen. 
Oxidative stress has been implicated in many human diseases. Activity of erythrocyte 
antioxidant enzymes is closely studied to reveal oxidative stress status in various 
pathological conditions. 
Herein we describe the recent updates regarding point mutations, which contribute to the 
decrease of antioxidant protection of erythrocytes. 
2. Point mutations in proteins and enzymes providing a metabolism of 
erythrocytes 
2.1 Point mutation in glucose transporter GLUT 1 
GLUT1 was the first glucose transporter isoform to be identified, and is one of 13 proteins 
that comprise the human equilibrative glucose transporter family. GLUT1 is a membrane-
spanning glycoprotein of 492 amino acids, containing 12 transmembrane domains with both 
N- and C-termini located in cytosol, and its gene being located on chromosome 1 (1p35-31.3) 
is composed of ten exons and nine introns. GLUT1 is expressed at the highest levels in the 
plasma membranes of proliferating cells forming the early developing embryo, in cells 
forming the blood-tissue barriers, in human erythrocytes and astrocytes, and in cardiac 
muscle (Carruthers еt al., 2009). Heterozygous mutations in the GLUT1 gene have been 
reported in sporadic patients and results in autosomal dominant pedigrees. Expression of 
mutant transporters resulted in a significant decrease in transport activity of GLUT1. 
Impaired glucose transport across brain tissue barriers is reflected by hypoglycorrhachia 
and results in epilepsy, mental retardation and motor disorders. The first autosomal 
dominant missense mutation (G272A) has been reported within the human GLUT1 gene 
and wos shared by three affected family members. Substitution of glycine-91 by site-
directed mutagenesis with either aspartate or alanine was studied in oocytes. The data agree 
with 3-O-methyl-glucose uptake into patient erythrocytes and indicate that the loss of 
glycine rather than a hydrophilic side chain (Gly91→Asp) defines the functional 
consequences of this mutation. (Klepper еt al., 2001). Recently, mutations in GLUT1 gene 
have been identified as a cause in some patients with autosomal dominant paroxysmal 
exercise-induced dyskinesias (PED). PED are involuntary intermittent movements triggered 
by prolonged physical exertion. Some patients had a predating history of childhood absence 
epilepsy and a current history of hemiplegic migraine as well as a family history of migraine 
(Schneider еt al., 2009). In certain cases PED was accompanied by hemolytic anemia with 
echinocytosis, and altered erythrocyte ion concentrations. Using a candidate gene approach, 
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a causative deletion of 4 highly conserved amino acids (Q282_S285del) in the pore region of 
GLUT1 was identified. Functional studies in Xenopus oocytes and human erythrocytes 
revealed that this mutation decreased glucose transport and caused a cation leak that alters 
intracellular concentrations of sodium, potassium, and calcium. In families where PED is 
combined with epilepsy, developmental delay, or migraine, but not with hemolysis or 
echinocytosis 2 GLUT1 mutations were identified (A275T, G314S) that decreased glucose 
transport but did not affect cation permeability (Weber еt al., 2008). The causative mutations 
for some forms of hereditary stomatocytosis have been found to result from mutations in 
SLC2A1, encoding GLUT1. Stomatocytosis was associated with a cold-induced cation leak, 
hemolytic anemia and hepatosplenomegaly but also with cataracts, seizures, mental 
retardation and movement disorder (Flatt  еt al., 2011).  
2.2 Point mutation in glycolysis enzymes 
2.2.1 Point mutation in hexokinase 
Hexokinase (HK) catalyses the phosphorylation of glucose to glucose-6-phosphate using 
adenosine triphosphate as a phosphoryl donor. The four isozymes of the HK family (HK1, 
HK2, HK3, and glucokinase) contribute to commit glucose to the glycolytic pathway, each of 
which is encoded by a separate gene. The predominant HK1 isozyme is expressed in the 
vast majority of cells and tissues, including cells that are strictly dependent on glucose 
uptake for their metabolic needs. While most tissues express more than one HK isozyme, 
erythrocytes glucose metabolism only depends on HK1 activity. HK1 is one of the rate-
limiting enzymes in erythrocytes glycolysis. Gene structure and exon-intron organization of 
the HK1 gene have been elucidated from a sequence of three contiguous genomic clones 
localized at human chromosome 10. The sequence spans about 131 kb, and consists of 25 
exons, which include 6 testis- and 1 erythroid-specific exons. The HK1 and erythroid-
specific HK-R transcripts being produced by using two distinct promoters. Thus, the first 
and second exons are specifically utilized for the erythroid-specific HK-R and ubiquitously 
expressed HK1 isozymes respectively (Kanno 2000; Murakami еt al., 2002; van Wijk at al., 
2003; Bonnefond еt al., 2009). In humans, mutations including nonsynonymous substitutions 
in the active site of HK1 and intragenic deletions have been shown to cause HK1 enzymatic 
deficiency associated with autosomal recessive severe nonspherocytic hemolytic anemia 
(Bonnefond еt al., 2009). Mutation affecting the substrate affinites of the enzyme, regulatory 
properties, heat stability have been described (Rijksen еt al., 1983; Magnani еt al., 1985). HK 
deficiency is a very rare disease with a clinical phenotype of hemolysis. PCR amplification 
and sequence of the cDNA in patients with HK deficiency revealed the presence of a 
deletion and of a single nucleotide substitution, both in heterozygous form. In particular, the 
deletion, 96 bp long, concerns nucleotides 577 to 672 in the HK cDNA sequence and was not 
found in the cDNAs of 14 unrelated normal subjects. The sequence of the HK allele without 
deletion showed a single nucleotide substitution from T to C at position 1667 which causes 
the amino acid change from Leu529 to Ser (Bianchi еt al., 1995). The T1667→C substitution, 
causing the amino acid change Leu529→Ser, is responsible for the complete loss of the 
hexokinase catalytic activity, while the 96 bp deletion causes a drastic reduction of the 
hexokinase activity (Bianchi еt al., 1997). A homozygous missense mutation in exon 15 
(2039C→G, HK Utrecht) of HK1, the gene that encodes red blood cell-specific hexokinase-R, 
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in a patient previously diagnosed with hexokinase deficiency has been reported. The 
Thr680→Ser substitution predicted by this mutation affects a highly conserved residue in 
the enzyme's active site that interacts with phosphate moieties of adenosine diphosphate, 
adenosine triphosphate, and glucose-6-phosphate inhibitor (van Wijk еt al. 2003). On the 
paternal allele in a patient with chronic hemolysis two mutations in the erythroid-specific 
promoter of HKI: 373A→C and 193A→G were identified. Transfection of promoter reporter 
constructs showed that the 193A→G mutation reduced promoter activity to 8%. Hence, 
193A→G is the first mutation reported to affect red blood cell-specific hexokinase specific 
transcription. On the maternal allele there was a missense mutation in exon 3: 278G→A, 
encoding an arginine to glutamine substitution at residue 93 (Arg93→Glu), affecting both 
hexokinase-1 and erytrocytes specific-hexokinase. This missense mutation was shown to 
compromise normal pre-mRNA processing. Reduced erythroid transcription of HK1 
together with aberrant splicing of both hexokinase-1 and erytrocytes specific-hexokinase 
results in HK deficiency and mild chronic hemolysis (de Vooght еt al. 2009). 
2.2.2 Point mutation in glucose-6-phosphate isomerase 
Glucose-6-phosphate isomerase (GPI) catalyzes interconversion of glucose-6-phosphate and 
fructose 6-phosphate in the Embden-Meyerhof glycolytic pathway. GPI is an essential 
enzyme for carbohydrate metabolism in all tissues. In humans, the GPI gene locus is located 
on chromosome 19, and the gene spans more than 40 kb, including 18 exons and 17 introns. 
The cDNA sequence encodes 558 amino acid residues. The enzyme consists of two identical 
subunits. In mammals, GPI can also act as an autocrine motility factor, neuroleukin, and 
maturation factor. GPI deficiency is a well-known congenital autosomal recessive disorder 
with the typical manifestation of nonspherocytic hemolytic anemia of variable severity in 
humans. GPI deficiency is one of the most common cause of congenital nonspherocytic 
hemolytic anemia caused by deficiency of glycolytic enzymes, the commonest being 
deficiency of glucose-6-phosphate dehydrogenase and pyruvate kinase. Patients with 
inherited GPI deficiency present with nonspherocytic anemia of variable severity and with 
neuromuscular dysfunction. Mutations in the GPI gene usually have negative influences on 
catalytic parameters, particularly k(cat), as well as structure stability. Mutations at or close 
to the active site, including R273H, H389R, and S278L, cause great damage to the catalytic 
function, yet those at distance can still reduce the magnitude of k(cat). At the nucleotide 
level, 29 mutations have been reported. Mutations decrease the enzyme tolerance to heat by 
mechanisms of decreasing packing efficiency (V101M, T195I, S278L, L487F, L339P, T375R, 
I525T), weakening network bonding (R75G, R347C, R347H, R472H, E495K), increasing 
water-accessible hydrophobic surface (R83W), and destabilizing the ternary structure 
(T195I, R347C, R347H, and I525T). A300P, L339P, and E495K mutations may also negatively 
affect the protein folding efficiency (Merkle S. at al., 1993; Kanno H. at al., , 1996; Kugler W. 
at al., 2000; Haller J.F. еt al., 2009; Haller J.F., еt al., 2010). The neurologically affected patient 
(GPI Homburg) is compound heterozygous for a 59 A→C (H20P) and a 1016 T→C (L339P) 
exchange. Owing to the insertion of proline, the H20P and L339P mutations are likely to 
affect the folding and activity of the enzyme. Point mutations identified at 1166 A→G 
(H389R) and 1549 C→G (L517V), which are located at the subunit interface showed no 
neurological symptoms. Thus mutations that lead to incorrect folding destroy both catalytic 
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(GPI) and neurotrophic activities, thereby leading to the observed clinical symptoms (GPI 
Homburg). Those alterations at the active site, however, that allow correct folding retain the 
neurotrophic properties of the molecule (GPI Calden) (Kugler, 1998). The similarity of the 
mutant enzymes to the allozymes found in human GPI deficiencies indicates the GPI 
deficient mouse mutants to be excellent models for the human disease (Padua et al., 1978; 
Pretsch et al., 1990). A heterozygous mouse mutant exhibiting approximately 50% of wild-
type GPI activity. Biochemical and immunological studies revealed no differences in 
physicochemical, kinetic and immunological properties between the erythrocytic enzyme of 
heterozygous and wild-type mouse. The genetic and physiological analyses provided no 
indications for further altered traits in heterozygous animals including fertility, viability and 
several other traits. Homozygous null mutants died at an early post-implantation stage of 
embryogenesis (West et al., 1990; Merkle et al., 1992). Homozygous GPI deficiency in 
humans are responsible for chronic nonspherocytic hemolytic anemia. The homozygous 
missense A346H mutation replacement in cDNA position 1040G→A, which causes a loss of 
GPI capacity to dimerize, which renders the enzyme more susceptible to thermolability and 
produces significant changes in erythrocyte metabolism was described in patient with 
chronic nonspherocytic hemolytic anemia (Repiso et al., 2005). Biochemical and molecular 
genetic studies performed with the enzyme variants of GPI Zwickau and GPI Nordhorn 
showed that in both cases the simultaneous occurrence of a single amino acid substitution 
affecting the active site, together with a nonsense mutation leading to the loss of major parts 
of the enzyme probably explains the severe clinical course of the disease (Huppke et al., 
1997). Molecular characteristics of erythrocytes GPI deficiency were described in Spanish 
patients with chronic nonspherocytic hemolytic anemia. Residual GPI activity in 
erythrocytes of around 7% (GPI-Catalonia), in an individual is homozygous for the missense 
mutation 1648A→G (Lys550→Glu) in exon 18 was described and residual activity in 
erythrocytes of around 20% (GPI-Barcelona), was found in a compound heterozygote for 
two different missense mutations: 341A→T (Asp113→Val) in exon 4 and 663T→G 
(Asn220→Lys) in exon 7. Molecular modeling using the human crystal structure of GPI as a 
model was performed to determine how these mutations could affect enzyme structure and 
function (Repiso et al., 2006). Chinese hamster (CHO) cell lines with ethylmethane sulfonate 
induced mutations in GPI and consequent loss of GPI activity have been reported. GPI 
activity was reduced by 87% in GroD1 isolated from this population. Expression cloning 
and sequencing of the cDNA obtained from GroD1 revealed a point mutation Gly189→ Glu. 
This resulted in a temperature sensitivity and severe reduction in the synthesis of 
glycerolipids due to a reduction in phosphatidate phosphatase (PAP). Overexpression of 
lipin 1 in the GPI-deficient cell line, GroD1 resulted in increased PAP activity, however it 
failed to restore glycerolipid biosynthesis. Fluorescent microscopy showed a failure of GPI-
deficient cells to localize lipin 1ǂ to the nucleus. Glucose-6-phosphate levels in GroD1 cells 
were 10-fold over normal. Lowering glucose levels in the growth medium partially restored 
glycerolipid biosynthesis and nuclear localization of lipin 1ǂ. Thus, GPI deficiency results in 
an accumulation of glucose-6-phosphate, and possibly other glucose-derived metabolites, 
leading to activation of mTOR and sequestration of lipin 1 to the cytosol, preventing its 
proper functioning. These results may also help to explain neuromuscular symptoms 
associated with inherited GPI deficiency (Haller et al., 2010; 2011). GPI deficiency was found 
to be the cause of recurrent haemolytic crises that has required frequent blood transfusion. 
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Hemolysis is often ameliorated by splenectomy (Neubauer et al., 1990; Shalev et al., 1994; 
Alfinito et al., 1994). GPI deficiency can become a clinically relevant consequence of the 
administration of drugs. GPI deficiency can lead to impairment of the system that removes 
free radicals generated by amoxicillin, thereby resulting in oxidation of hemoglobin and 
destabilization of erythrocytes membranes, with acute hemolysis and severe 
hemoglobinuria (Rossi et al., 2010). 
2.2.3 Point mutation in phosphofructokinase 
Phosphofructo-1-kinase (PFK) is a tetrameric enzyme that phosphorylates fructose-6-
phosphate to fructose-1,6-bisphosphate, committing glucose to glycolysis. Three PFK 
isoenzymes, encoded by separate genes, have been identified in mammals: muscle-type 
(PFKM), liver-type (PFKL), and platelet-type (PFKP), all of which are expressed in a tissue 
specific manner. Skeletal muscle expresses only PFKM homotetramers, liver mainly PFKL 
homotetramers, while erythrocytes contain PFKM and PFKL heterotetramers (Vora et al., 
1983). Inherited deficiency of muscle PFK is known to occur in man and dog (Vora et al., 
1983; Skibild et al., 2001). PFK deficiency was the first recognized disorder that directly 
affects glycolysis. Ever since the discovery of the disease in 1965, a wide range of 
biochemical, physiological and molecular studies of the disorder have been carried out 
(Nakajima et al., 2002). Several mutations in PFKM cause type VII glycogen storage disease 
(GSDVII), which is a rare disease described by Tarui (Tarui’s disease). GSDVII is 
characterized by the coexistence of a muscle disease and a hemolytic process. Clinical 
manifestations of the disease range from the severe infantile form, leading to death during 
childhood, to the classical form, which presents mainly with exercise intolerance. Typically, 
the disease begins in early childhood and consists of easy fatigability, transient weakness 
and muscle cramps and myoglobinuria after vigorous exercises (Vora et al., 1987; García et 
al., 2009). A G-to-A transition at codon 209-in exon 8 of the PFK-M gene, changing an 
encoded Gly to Asp, is responsible for the GSDVII in a homozygous French Canadian 
patient. The Swiss patient is a genetic compound, carrying a G-to-A transition at codon 100 
in exon 6 (Arg to Gln) and a G-to-A transition at codon 696 in exon 22 (Arg to His) (Raben et 
al., 1995). PFK deficiency include isolated hemolytic anemia, compensated hemolysis or 
asymptomatic state (Etiemble et al., 1983; Fogelfeld et al., 1990). The concomitant haemolysis 
in patients with inherited PFK deficiency of the muscle isoenzyme may be explained by a 
diminished erythrocyte deformability due to Ca2+ overload (Ronquist et al., 2001). PFK 
deficiency include early-onset neonatal seizures (Al-Hassnan et al., 2007). Portal and 
mesenteric vein thrombosis in patient with a known case of PFK deficiency has been 
described (Madhoun et al., 2011). 
2.2.4 Point mutation in aldolase 
Aldolase, a homotetrameric protein encoded by the ALDOA gene, converts fructose-1,6-
bisphosphate to dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. Three 
isozymes are encoded by distinct genes. The sole aldolase present in erythrocytes and 
skeletal muscle is the A isozyme. Aldolase B is mainly expressed in the liver, kidney and 
small intestine, where it plays a role in exogenous fructose utilization. Aldolase C is 
expressed predominantly in the brain. Aldolase B deficiency has been widely described in 
humans, because it causes hereditary fructose intolerance, which is an autosomal recessive 
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disease that may induce severe liver damage, leading, in extreme cases, to death if fructose 
is not eliminated from the diet. To date, nearly 25 HFI-related aldolase B mutants have been 
identified. In contrast, cases of aldolase A deficiency, which has been associated with 
nonspherocytic haemolytic anemia, are much rarer (Esposito et al., 2004). Human aldolase A 
is composed of four identical subunits encoded by a single gene located on chromosome 16 
(16q22–q24). Aldolase A deficiency has been reported as a rare, autosomal recessive 
disorder (Kreuder et al., 1996; Yao et al., 2004). Alterations in the aldolase A gene leading to 
amino acid substitutions: Asp128→Gly (Kishi et al., 1987), Glu206→Lys (Kreuder et al., 
1996), Gly346→Ser (Esposito et al., 2004) have been described. The Glu206→Lys mutation 
destabilizes the aldolase A tetramer at the subunit interface, the Gly346→Ser mutation limits 
the flexibility of the C-terminal region. Biochemical and thermodynamic data are available 
for the Asn128→Gly mutant have never been characterized. Yao D.C. et al. described the 
case of a girl of Sicilian descent with aldolase A deficiency. Clinical manifestations included 
transfusion-dependent anemia until splenectomy at age 3 and increasing muscle weakness, 
with death at age 4 associated with rhabdomyolysis and hyperkalemia. Sequence analysis of 
the ALDOA coding regions revealed 2 novel heterozygous ALDOA mutations in conserved 
regions of the protein. The paternal allele encoded a nonsense mutation, Arg303X, in the 
enzyme-active site. The maternal allele encoded a missense mutation, Cys338→Tyr, 
predicted to cause enzyme instability as reported (Yao et al., 2004). Hemolytic crisis in 
patients with aldolase A deficiency can be provoked by fever (Kiriyama et al., 1993) and  
upper respiratory infections (Miwa et al., 1981). 
2.2.5 Housekeeping genes in glyceraldehyde 3-phosphate dehydrogenase 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) specifically catalyzes the 
simultaneous phosphorylation and oxidation of glyceraldehyde-3-phosphate to 1,3-
biphosphoglycerate. GAPDH comprises a polypeptide chain of 335 amino acids. Structural 
studies identified two regions, namely the glyceraldehyde-3-phosphate catalytic site and the 
nicotinamide adenine dinucleotide binding site. The glycolytic function mainly relies on 
critical amino acids that include Cys152 and His179, and on its tetrameric structure 
composed of four identical 37-kDa subunits (Colell et al., 2009).  GAPDH was considered a 
classical glycolytic protein involved exclusively in cytosolic energy production. However, 
recent evidence suggests that it is a multifunctional protein displaying diverse activities 
distinct from its conventional metabolic role. New investigations establish a primary role for 
GAPDH in a variety of critical nuclear pathways apart from its already recognized role in 
apoptosis. These new roles include its requirement for transcriptional control of histone 
gene expression, its essential function in nuclear membrane fusion, its necessity for the 
recognition of fraudulently incorporated nucleotides in DNA, and its mandatory 
participation in the maintenance of telomere structure. Other investigations relate a 
substantial role for nuclear GAPDH in hyperglycemic stress and the development of 
metabolic syndrome. GAPDH is a highly conserved gene and protein, with a single mRNA 
transcribed from a unique gene (Sirover 1997, 2005, 2011). GAPDH has been referred to as a 
"housekeeping" protein and based on the view that GAPDH gene expression remains 
constant under changing cellular conditions, the levels of GAPDH mRNA have frequently 
been used to normalize northern blots (Tatton, 2000). Evidence of an impairment of GAPDH 
glycolytic function in Alzheimer's and Huntington's disease subcellular fractions despite 
unchanged gene expression has been reported (Mazzola & Sirover, 2001). 
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2.2.6 Point mutation in phosphoglycerate kinase 
Phosphoglycerate kinase (PGK) plays a key role for ATP generation in the glycolytic 
pathway. The PGK, which exists universally in various tissues of various organisms, is 
encoded by a single structural gene on the X-chromosome q13 in humans. The PGK consists 
of 417 amino acid residues with acetylserine at the NH2-terminal and isoleucine at the 
COOH-terminal and is a monomeric enzyme that is expressed in all tissues (Huang et al. 
1980; Maeda et al. 1991). PGK deficiency is generally associated with chronic hemolytic 
anemia, although it can be accompanied by either mental retardation or muscular disease 
(Cohen-Solal et al. 1994). The structure of some PGK mutants has been described. PGK 
Matsue variant is a point mutation, a T/A→C/G transition in exon 3, that cause Leu88→Pro 
substitution associated with severe enzyme deficiency, congenital nonspherocytic hemolytic 
anemia, and mental disorders (Maeda et al. 1991). PGK Shizuoka variant is a single 
nucleotide substitution from guanine to thymine at position 473 of PGK messenger RNA, 
associated with chronic hemolysis and myoglobinuria. This nucleotide change causes a 
single amino acid substitution from Gly157→Val (Fujii et al. 1992). PGK Créteil variant 
arises from a G→A nucleotide interchange at position 1022 in cDNA (exon 9), resulting in 
amino acid substitution Asp314→Asn associated with rhabdomyolysis crises but not with 
hemolysis or mental retardation. PGK Amiens/New York variant, which is associated with 
chronic hemolytic anemia and mental retardation is a point mutation, an A→T nucleotide 
interchange at position 571 in cDNA (exon 5); this leads to amino acid substitution 
Asp163→Val (Cohen-Solal et al., 1994; Flanagan et al., 2006). Variants of PGK Barcelona and 
PGK Murcia are described in Spain. PGK Barcelona variant, which causes chronic hemolytic 
anemia associated with progressive neurological impairment is a point mutation, 140 T→A 
substitution that produces an Ile46→Asn change. The increase of 2,3-bisphosphoglycerate 
and the decrease of adenosine triphosphate levels in erythrocytes are the detected metabolic 
changes that could cause hemolytic anemia. PGK Murcia variant is a point mutation, 958 
G→A transition that cause a Ser319→Asn substitution. The crystal structure of porcine PGK 
was used as a molecular model to investigate how these mutations may affect enzyme 
structure and function. In both cases – the mutations did not modify any of the PGK binding 
sites for ATP or 3PG, so their effect is probably related to a loss of enzyme stability rather 
than a decrease of enzyme catalytic function (Noel N. et al., 2006; Ramírez-Bajo M.J. et al., 
2011). Mutants PGK München (Krietsch et al., 1980), PGK Herlev (Valentin et al., 1998), PGK 
Uppsala (Hjelm et al., 1980), PGK San Francisco (Guis et al., 1987), PGK II (Huang et al., 
1980), PGK Michigan, PGK Tokyo (Cohen-Solal et al., 1994) are also described. 
2.2.7 Point mutation in phosphoglycerate mutase 
Phosphoglycerate mutase (PGAM) is a glycolytic enzyme that catalyses the interconversion 
of 2-phosphoglycerate and 3-phosphoglycerate, with 2,3-bisphosphoglycerate being 
required, in mammals, as a co-factor. In mammals, PGAM is present in three isozymes 
which result from the homodimeric and heterodimeric combinations of two different 
subunits, M and B, coded by two different genes, although the gene coding subunit B is 
unknown. Only the homodimer BB is present in erythrocytes. Only one PGAM BB 
deficiency has been reported. In a patient with clinical diagnosis of Hereditary 
Spherocytosis and partial deficiency (50%) of erythrocytes PGAM activity, a homozygous 
point mutation with cDNA 690G→A substitution that produces a Met230→Ile change has 
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recently been reported. The mutated PGAM shows an abnormal behaviour on ion-exchange 
chromatography and is more thermo-labile that the native enzyme. The increased instability 
of the mutated enzyme can account for the decreased erythrocytes PGAM activity (Repiso et 
al., 2005; de Atauri et al., 2005).  
2.2.8 Point mutation in enolase 
Enolase, an essential enzyme of glycolysis and gluconeogenesis, catalyses the 
interconversion of 2-hosphoglyceric acid and phosphoenolpyruvate. Enolases from most 
species are dimeric, with subunit molecular masses of 40000–50000 Da. Mammals have three 
genes for enolase, coding for the ǂ, ǃ and Ǆ subunits; the subunits associate to form both 
homo- and heterodimers. The ǂ gene is expressed in many tissues, Ǆ primarily in neurones 
and ǃ in muscle (Zhao et al., 2008). Erytrocytes enolase deficiency is rare, and its 
pathogenesis, inheritance and clinical manifestation have not been firmly established. 
Enolase deficiency is known to be associated with chromosome 1p locus mutations (1 pter-
p36.13) and to cause chronic nonspecific hemolytic anemia (Boulard-Heitzmann et al., 1984). 
Lachant et al. (1986) described four generations of a Caucasian family with hereditary 
erytrocytes enolase deficiency. Stefanini (1972) described chronic hemolytic anemia 
associated with erythrocyte enolase deficiency exacerbated by ingestion of nitrofurantoin. 
2.2.9 Point mutation in pyruvate kinase 
Pyruvate kinase (PK) catalyses the last step of the Embden–Meyerhof metabolic pathway, in 
which an ATP molecule is produced. Among the four PK isozymes present in humans (M1, 
M2, L and R), both PK-L (found in the liver, kidney and gut) and PK-R present in 
erythrocytes are encoded by the same gene, which is localised on hromosome 1q21. The 
respective expression of these two isozymes is under the control of specific promoters 
leading to structural differences in the N-terminal part of the protein. PK-R is a 574 amino 
acid-long protein, which associates into tetramers according to a double dyad symmetry 
pattern, resulting in allosteric enzymatic kinetics. PK deficiency is the most frequent red cell 
enzymatic defect responsible for hereditary nonspherocytic hemolytic anemia and is 
transmitted according to a recessive autosomal mode. Based on the gene frequency of the 
1529A mutation in the white population and on its relative abundance in patients with 
hemolytic anemia caused by PK deficiency, the prevalence of PK deficiency is estimated at 
51 cases per million white population (Beutler et al., 2000). The degree of haemolysis varies 
widely, ranging from very mild or fully compensated forms, to life-threatening neonatal 
anemia and jaundice necessitating exchange transfusions. Heterozygous carriers usually 
display very mild symptoms. Therefore, the defect is frequently ignored and its prevalence 
is difficult to establish. Severe disorders are described in homozygous or compound 
heterozygous patients (Zanella et al., 2005). According to the most recent database, more 
than 180 mutations have been reported on the PK-LR gene. Two mutations, both located in 
exon 11, are recurrent (Arg510 → Gln, Arg486 → Trp). Arg510→ Gln is the most frequent 
mutation found in northern Europe, central Europe and the USA (Pissard S. at al., 2006, as 
citated Wang et al., 2001) and Arg486 → Trp in southern Europe (Spain, Portugal and Italy) 
and in France (Pissard et al., 2006, as citited Zanella et al, 1997; Zarza et al, 1998; Pissard et 
al., 2006). The most frequent mutations of PKLR gene in the Indian population appear to be 
1436G→A (19.44%), followed by 1456C→T (16.66%) and 992A→G (16.66%) (Kedar et al., 
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2009). Erythrocyte PK plays an important role as an antioxidant during erythroid 
differentiation. Glycolytic inhibition by erythrocyte PK gene mutation augmented oxidative 
stress, leading to activation of hypoxia-inducible factor-1 as well as downstream 
proapoptotic gene expression (Aisaki et al., 2007). Extended molecular analysis is useful for 
studying how several interacting gene mutations contribute to the clinical variability of 
pyruvate kinase deficiency (Perseu et al., 2010). 
2.2.10 Point mutation in glucose-6-phosphate dehydrogenase 
Glucose 6-phosphate dehydrogenase (G6PD) is a ubiquitous  enzyme, which is critical in the 
redox metabolism of all aerobic cells. It catalyzes the first, rate-limiting step of the pentose 
phosphate pathway, coupled to NADPH synthesis and to ribose availability which is 
essential for the production of nucleotide coenzymes and replication of nucleic acids 
(Sodiende O., 1992). The pentose phosphate pathway is the unique source of NADPH, 
which enables erytrocytes to counterbalance the oxidative stress triggered by several 
oxidant agents preserving the reduced form of glutathione. GSH protects the sulfhydryl 
groups in hemoglobin and in the red cell membrane from oxidation (Mason et al., 2007). 
G6PD is a dimer and each subunit contains a single active site. G6PD-enzyme is encoded by 
a human X-linked gene (Xq2.8) consisting of 13 exons and 12 introns, spanning nearly 20 kb 
in total. G6PD gene is probably the most polymorphic locus in humans, with over 400 allelic 
variants known (Minucci et al., 2009). G6PD, the most common enzyme deficiency 
worldwide, causes a spectrum of disease including neonatal hyperbilirubinemia, acute 
hemolysis, and chronic hemolysis. Persons with this condition also may be asymptomatic. 
Approximately 400 million people are affected worldwide. Homozygotes and heterozygotes 
can be symptomatic, although the disease typically is more severe in persons who are 
homozygous for the deficiency. Different gene mutations cause different levels of enzyme 
deficiency, with classes assigned to various degrees of deficiency and disease manifestation. 
Acute hemolysis is caused by exposure to an oxidative stressor such as infection, some foods 
(fava beans), drugs or various chemicals. The variant that causes chronic hemolysis is 
uncommon because it is related to sporadic gene mutation rather than the more common 
inherited gene mutation (Frank, 2005). About 160 mutations have been reported, most of 
which are single-base substitutions leading to amino acid replacements (Minucci et. al., 
2009). Mutations are classified into four types, according to their clinical effects. Several 
variants, such as the the Mediterranean variant, reach the polymorphism (Wajcman et. al., 
2004). The Mediterranean variant of G6PD deficiency is due to the C563CT point mutation, 
leading to replacement of Ser with Phe at position 188, resulting in acute haemolysis 
triggered by oxidants (Ingrosso et. al., 2002). Individuals with such mutations seem to have 
enjoyed a selective advantage because of resistance to falciparum malaria. Different 
mutations, each characteristic of certain populations are found.The most common African 
mutation G6PD is 202A376G. G6PD Mediterranean (563T) is found in Southern Europe, the 
Middle East and in the Indian subcontinent (Beulter, 1996). 
2.2.11 Point mutation in 6-phosphogluconate dehydrogenase 
The 6-phosphogluconate dehydrogenase (6PGDH) is the third enzyme of the oxidative 
branch of the pentose phosphate pathway. This pathway has two major functions: the 
production of ribulose 5-phosphate which is required for nucleotide synthesis, and the 
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generation of NADPH which provides the major reducing power essential to protect the cell 
against oxidative stress and a variety of reductive biosynthetic reactions, particularly lipid 
production. Thus, 6PGDH plays a critical role in protecting cells from oxidative stress (He et 
al., 2007). Few cases of erytrocytes 6PGD deficiency in humans have been described. The 
episodic hemolytic events with jaundice in patients with 6PGD deficiency may be the result 
of a defective erythrocytes ability to counteract conditions of marked oxidative stress as 
happens at birth and following traumatic events. The presence of 6PGD deficiency could be 
mistaken for a partial G6PD deficiency if the assay of G6PD activity was performed without 
correcting for 6PGD activity (Vives Corrons et al., 1996; Caprari et al., 2001). 
2.3 Point mutation in glutathione synthetase 
Glutathione (GSH) is the most abundant intracellular thiol in living aerobic cells. GSH is 
present in millimolar concentrations in most mammalian cells and it is involved in several 
fundamental biological functions, including free radical scavenging, detoxification of 
xenobiotics and carcinogens, redox reactions, biosynthesis of DNA, proteins and 
leukotrienes, as well as neurotransmission/neuromodulation. It has been assigned several 
critical functions: protection of cells against oxidative damage; involvement in amino acid 
transport; participation in the detoxification of foreign compounds; maintenance of protein 
sulfhydryl groups in a reduced state; and as a cofactor for a number of enzymes. GSH is 
found in low levels in diseases in which increasing evidence implicate oxidative stress in the 
development of the disease, for example retinopathy of prematurity, necrotizing 
enterocolitis, bronchopulmonary dysplasia, patent ductus arteriosus and asthma. GSH is 
metabolised via the gamma-glutamyl cycle, which is catalyzed by six enzymes (Polekhina  
at al., 1999; Njålsson et al., 2005; Norgren et al., 2007). GSH is synthesized from glutamate, 
cysteine and glycine. The final step in its synthesis is catalysed by the enzyme glutathione 
synthetase (GS) The human GS enzyme is a homodimer with 52 kDa of subunits containing 
474 amino acid residues, encoded by a single-copy gene located on chromosome 20q11.2 
(Webb et al., 1995; Njålsson et al., 2005). 
GS deficiency is a rare autosomal recessive disorder. Since the human genome contains only 
one GS gene, the various clinical forms of GS deficiency reflect different mutations or 
epigenetic modifications in the GS gene. Thus GSH acts as a feedback inhibitor of the initial 
step in its biosynthesis, in patients with hereditary deficiency of GS the lack of GSH leads to 
the formation of increased amounts of g-glutamylcysteine which is converted into 5-
oxoproline by g-glutamyl cyclotransferase and excreted in massive amounts. Shi et al. 
identified seven mutations at the GS locus on six alleles: one splice site mutation, two 
deletions and four missense mutations and in patients with 5-Oxoprolinuria (pyroglutamic 
aciduria) resulting in GS deficiency and homozygous missense mutation in an individual 
affected by a milder-form of the GS deficiency, which is apparently restricted to erythrocytes 
and only associated with haemolytic anaemia (Shi, et al., 1996). Japanese patients with 
chronic nonspherocytic hemolytic anemia were found to have decreased GS activity and the 
others were moderately deficient in GCS. Hemolytic anemia was their only manifestation, 
and neither 5-oxoprolinemia nor 5-oxoprolinuria, which are usually associated with to 
generalized type of glutathione synthetase deficiency, was noted in patients. (Hirono et al., 
1996). Dahl N. at al. described thirteen different point mutations. In vitro analysis of 
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naturally occurring missense mutations showed that mutations could affect the stability, 
catalytic capacity and substrate affinities of the enzyme. Four mutant cDNAs were 
investigated with the mutations resulting in Leu188→Pro, Tyr270→Cys, Tyr270→His and 
Arg283→Cys, respectively. Each of the four mutations resulted in a considerable decrease of 
enzymatic activity to levels corresponding to 1 to 12% of the wild-type control value, 
confirming that these mutations were pathogenic. Clinically affected patients present with 
severe metabolic acidosis, 5-oxoprolinuria, increased rate of hemolysis, hemolytic anemia, 
neonatal jaundice and defective function of the central nervous system. A milder form of GS 
deficiency apparently restricted to erythrocytes, is associated with decreased erythrocyte 
GSH levels and hemolytic disease, which is usually well compensated. Complete loss of 
function of both GS alleles is probably lethal. Missense mutations will account for the 
phenotype in the majority of patients with severe GS deficiency (Dahl et al., 1997). A 141-bp 
deletion corresponding to the entire exon 4, whilst the corresponding genomic DNA 
showed a G491→A homozygous splice site mutation, and a C847→T (Arg283→ Cys) 
mutation in exon 9 are described in patients with GS deficiency and Fanconi nephropathy 
(Al-Jishi et al., 1999). A homozygous state for 656 A→G, a 808 T→C mutation of GS gene in 
patients with chronic haemolysis and markedly reduced erythrocytes was found in Spain 
(Corrons, et al., 2001). Patients with GS deficiency can be divided into three groups. Mildly 
affected patients have mutations affecting the stability of the enzyme, causing a 
compensated haemolytic anaemia; moderately affected patients have, in addition, metabolic 
acidosis; and severely affected patients also develop neurological defects and show 
increased susceptibility to bacterial infections. Moderately and severely affected patients 
have mutations that compromise the catalytic properties of the enzyme. 5-Oxoprolinuria 
appears in all three groups, but is more pronounced in the two latter groups (Njålsson .et al., 
2005). 5-Oxoproline is able to promote both lipid and protein oxidation, to impair brain 
antioxidant defenses and to enhance hydrogen peroxide content, thus promoting oxidative 
stress, and is a mechanism that may be involved in the neuropathology of GS deficiency 
(Pederzolli et al., 2010). Approximately 25% of patients with hereditary GS deficiency die 
during childhood. Even though the correlation between phenotype and genotype in these 
patients is complex, an indication of the phenotype can be based on the type of mutation 
involved (Njålsson et al., 2005). Severe GS deficiency is associated with progressive retinal 
dystrophy of the rod-cone type, affecting the central retina with advanced macular edema in 
adulthood. The retinal degenerative changes in GS deficiency may be the result of the 
increased oxidative stress accumulated generally in the retina and also apparent in the 
macular area, and an insufficient level of the free radical scavenger GSH. Patients with GS 
deficiency may represent a model of the retinal response to oxidative stress in humans 
(Burstedt et al., 2009). Recently 30 different mutations in the GSS gene have been identified 
(Njålsson et al., 2005). The severe form of GS deficiency usually present in the neonatal 
period, is characterized by acute metabolic acidosis, hemolytic anemia and progressive 
encephalopathy (Iyori et al., 1996; Yapicioğlu et al., 2004). Diagnosis of GS deficiency is 
made by clinical presentation and detection of elevated concentrations of 5-oxoproline in 
urine and low GS activity in erythrocytes or cultured skin fibroblasts. Diagnosis can be 
confirmed by mutational analysis. The most important determinants for outcome and 
survival in patients with GS deficiency are early diagnosis and early initiation of treatment. 
Presently, GS deficiency is not included in newborn screening programmes in Europe. As 
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outcome depends significantly on early start of treatment, routine inclusion of this 
disorder in newborn screening panels should be considered. Treatment consists of the 
correction of acidosis, blood transfusion, and supplementation with antioxidants (Simon 
et al., 2009). Patients with GS deficiency are given vitamins C and E to boost their 
antioxidant levels, and bicarbonate to correct metabolic acidosis (Jain et al.,1994; Ristoff et 
al., 2001; Njålsson et al., 2005). 
2.4 Point mutation in glutathione reductase 
Glutathione reductase (GR) is a key enzyme required for the conversion of oxidized 
glutathione (GSSG) to reduced glutathione (GSH) concomitantly oxidizing reduced 
nicotinamide adenine dinucleotide phosphate (NADPH). GR is a homodimeric flavoprotein 
with a subunit Mr of 52.4 kDa. Its 2 identical redox active sites are formed by residues from 
both subunits, implying that monomeric GR is not active. Human GR is encoded by a single 
gene, located on chromosome 8p21.1 and consisting of 13 exons. GR consists of 
apoglutathione reductase (apoGR) and flavin adenine dinucleotide (FAD) as a prosthetic 
group (Kamerbeek et al., 2007).  
Acquired FAD deficiency due to low amounts of riboflavin (vitamin B2) in the diet (or 
failure to convert it sufficiently to FAD) may result in inactive apoGR. In that case GR 
activity can be restored by riboflavin administration. Due to inherited mutations, the GR 
protein can be absent or exhibit low catalytic activity. Whereas inherited glutathione 
reductase deficiency is rare, FAD deficiency is common in malnourished populations. The 
clinical symptoms of GR deficiency include reduced lifespan of erythrocytes, cataract, and 
favism (hemolytic crises after eating fava beans). A 2246-bp deletion in DNA, which results 
in unstable and inactive GR and a premature stop codon on one allele and a substitution of 
glycine 330, a highly conserved residue in the superfamily of NAD(P)H-dependent disulfide 
reductases, into alanine on the other allele were described in the GR gene in patients with 
clinical GR deficiency (Kamerbeek et al., 2007). GR deficiency may alter the clinical 
manifestation of an unstable hemoglobinopathy (Mojzikova at al., 2010) and  may be the 
cause of neonatal hyperbilirubinemia (Casado et al., 1995). GR deficiency state can be 
asymptomatic as the residual enzyme activity might be sufficient to maintain the reduced 
glutathione level to prevent oxidative stress (Nakashima et al., 1978). A study on 1691 
individuals from Saudi Arabia to determine the overall frequency of GR deficiency has been 
conducted. The overall frequency of genetic GR deficiency was 24.5% and 20.3% in males 
and females respectively. In addition, 17.8% of males and 22.4% of females suffered from GR 
deficiency due to riboflavin deficiency. This could be easily corrected by dietary 
supplementation with riboflavin. No cases of severe GR deficiency were identified (el-
Hazmi et al., 1989; Warsy et al., 1999). 
2.5 Point mutation in glutathione peroxidase 
Glutathione peroxidase (GPx) is the general name of an enzyme family with peroxidase 
activity whose main biological role is to protect the organism from oxidative damage. There 
are eight well-characterized mammalian selenoproteins, including thioredoxin reductase 
and four isozymes of glutathione peroxidase. GPx1 is a homotetrameric selenoprotein and 
one of a family of peroxidases that reductively inactivate peroxides using glutathione as a 
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source of reducing equivalents. GPx1 is found in the cytoplasm and mitochondria of all cell 
types, whose preferred substrate is hydrogen peroxide (Dimastrogiovanni et al., 2010). 
GPx1 has been implicated in the development and prevention of many common and 
complex diseases, including cancer and cardiovascular disease (Lubos at al., 2011). The T 
allele of the GPx1 rs1050450 (C→ T) gene variant is associated with reduced enzyme 
activity. Significant association between the T allele and peripheral neuropathy in subjects 
with diabetes is observed (Tang et al., 2010). Takapoo at al. using a murine model of GPx1 
deficiency (Gpx1(+/-)) found elevated hydrogen peroxide levels and increased secretion of 
the pro-inflammatory immunomodulator cyclophilin A (CyPA) in both arterial segments 
and cultured smooth muscle cells as compared to wild type. Reduction in vascular cell GPx1 
activity and the associated increase in oxidative stress cause CyPA-mediated paracrine 
activation of smooth muscle cells. These findings identify a mechanism by which an 
imbalance in antioxidant capacity may contribute to vascular disease (Takapoo et al., 2011). 
Mice with a disrupted GPx1 gene (Gpx1 0/0) developed myocarditis after coxsackievirus B3 
infection, whereas infected wild-type mice (Gpx1 +/+) were resistant. Thus, GPx1 provides 
protection against viral-induced damage in vivo due to mutations in the viral genome of a 
benign virus (Beck et al., 1998). The deficiency of GPx1 promotes atherogenesis (Lubos et al., 
2011). Severe acute hemoglobinemia and hemoglobinuria were described as a result a 
hereditary heterozygous GPx deficiency in Japan (Gondo et al., 1992). Patients with reduced 
GPx activity are at a high risk of developing carbamazepine-induced hemolytic crisis 
and/or aplastic crisis (Yamamoto et al., 2007). 
2.6 Point mutation in peroxiredoxin 
Peroxiredoxin (Prx) is a scavenger of hydrogen peroxide and alkyl hydroperoxides in living 
organisms. Six distinct mammalian Prx isozymes, types 1 to 6, have been detected in a 
wide range of tissues, and these have been shown to have strong antioxidant activities in 
vitro. In addition to their antioxidant activity, Prxs have been implicated in a number of 
cellular functions (Lee et al., 2003). Prx2 is an antioxidant enzyme that uses cysteine 
residues to decompose peroxides. Prx2 is the third most abundant protein in erythrocytes, 
and competes effectively with catalase and glutathione peroxidase to scavenge low levels 
of hydrogen peroxide, including that derived from hemoglobin autoxidation (Low, et al., 
2008). Mice lacking Prdx1 are viable and fertile but have a shortened lifespan owing to the 
development of severe haemolytic anaemia and several malignant cancers, both of which 
are also observed at increased frequency in heterozygotes. The haemolytic anaemia is 
characterized by an increase in erythrocyte reactive oxygen species, leading to protein 
oxidation, haemoglobin instability, Heinz body formation and decreased erythrocyte 
lifespan (Neumann et al., 2003). Point mutations in gene Prx2 in humans are not 
described.  
2.7 Point mutation in superoxide dismutase 1 
Superoxide dismutase 1 (SOD1) is a primarily cytosolic enzyme of the cellular oxidative 
defense and acts as a protein homodimer with each monomer containing one complexed 
copper and zinc ion. Point mutations scattered throughout the sequence of Cu,Zn 
superoxide dismutase 1 (SOD1) cause a subset of amyotrophic lateral sclerosis (ALS) 
cases. ALS is a progressive neurodegenerative disorder affecting motor neurons (Ip et al., 
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2011). The 140 Cu,Zn SOD1 gene mutations associated with ALS is described (Giannini et 
al., 2010). Variable penetrance and predominant lower motor neuron involvement are 
common characteristics in patients bearing mutations in exon 3 of the SOD1 gene (del 
Grande et al., 2011). Some mutations are associated with a long survival time, while 
others are linked to a very rapid progression (Syriani et al., 2009). With mild mechanical 
trauma which causes no major tissue damage, the G93A-SOD1 gene mutation alters the 
balance between pro-apoptotic and pro-survival molecular signals in the spinal cord 
tissue, leading to a premature activation of molecular pathways implicated in the natural 
development of ALS (Jokic et al., 2010). Mitochondria have shown to be an early target in 
ALS pathogenesis and contribute to the disease progression. Morphological and 
functional defects in mitochondria were found in both human patients and ALS mice 
overexpressing mutant SOD1. Axonal transport of mitochondria along microtubules is 
disrupted in ALS (Shi et al., 2010). Abnormal neuronal connectivity in primary motor 
cortex resulting from the G93A-SOD1 mutation might extend to adjacent regions and 
promote development of cognitive/dementia alterations frequently associated with ALS 
(Spalloni et al. 2011). Mutant SOD1 can alter cell cycle in a cellular model of ALS. 
Modifications in cell cycle progression could be due to an increased interaction between 
mutant G93A SOD1 and Bcl-2 through the cyclin regulator p27 (Cova et al., 2010). The 
D90A mutation has been identified in recessive, dominant, and apparently sporadic cases. 
A→C exchange at position 272 in the SOD1 gene is detected. This mutation results in an 
amino acid substitution of alanine for aspartate at position 90 (D90A). D90A in 
heterozygous state may cause predominant upper motor neuron phenotype with very 
slow progression (Luigetti et al., 2009). Oxidative stress markers have been found in 
nervous and peripheral tissues of familial and sporadic ALS patients (Cova et al., 2010). 
Lipid peroxidation in the erythrocytes of ALS patients was significantly increased with 
respect to controls (Babu et al., 2008). Recently described chronic, but moderate 
regenerative, haemolytic anaemia of aged SOD1-knockout mice is associated with 
erythrocytes modifications and sensitivity to both intra- and extra-vascular haemolysis 
(Starzyński et al., 2009). Deficiency of the SOD1 gene causes anemia and autoimmune 
responses against erythrocytes. Severity of anemia and levels of intracellular reactive 
oxygen species are positively correlated. Oxidation-mediated autoantibody production 
may be a more general mechanism for autoimmune hemolytic anemia and related 
autoimmune diseases. Shift in glucose metabolism to the pentose phosphate pathway and 
decrease in the energy charge potential of erythrocytes, increase in reactive oxygen 
species due to SOD1 deficiency accelerate erythrocytes destruction by affecting carbon 
metabolism and increasing oxidative modification of lipids and proteins. The resulting 
oxidation products are antigenic and, consequently, trigger autoantibody production, 
leading to autoimmune responses (Iuchi et al., 2007, 2009, 2010). 
2.8 Point mutation in catalase 
Catalase is an important anti-oxidant enzyme and physiologically maintains tissue and 
cellular redox homeostasis, thus plays a central role in defense against oxidative stress, it is 
the main regulator of hydrogen peroxide metabolism. Catalase is a tetramer of four 
polypeptide chains, each over 500 amino acids, it contains four porhyrin heme (iron) groups 
that allow the enzyme to react with hydrogen peroxide (Uchida et al., 2011). 
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Catalase deficiency in blood is known as acatalasemia. Deficiency of catalase may cause 
high concentrations of hydrogen peroxide and increase the risk of the development of 
pathologies for which oxidative stress is a contributing factor. Hydrogen peroxide at high 
concentrations is a toxic agent, while at low concentrations it appears to modulate some 
physiological processes such as signaling in cell proliferation, apoptosis, carbohydrate 
metabolism, and platelet activation. Benign catalase gene mutations in 5' noncoding region 
and intron 1 have no effect on catalase activity and are not associated with a disease. 
Decreases in catalase activity in patients with tumors is more likely to be due to decreased 
enzyme synthesis rather than to catalase mutations. Acatalasemia, the inherited deficiency 
of catalase has been detected in 11 countries (Góth et al., 2004). The molecular defects in the 
catalase gene, levels of m-RNA and properties of the residual catalase studied by scientists 
are reviewed in human (Japanese, Swiss and Hungarian) and non-human (mouse and 
beagle dog) acatalasemia. Japanese acatalasemia-I, the G to A transition at the fifth position 
of intron 4 of the catalase gene, limits the correct splicing of the mRNA, resulting in trace 
quantities of catalase with normal properties. The bicistronic microRNA miR-144/451 can 
influence gene expression by altering the activity of a key transcriptional program factor, 
impacting anti-oxidant-encoding genes like catalase (Yu et al., 2010). Hungarian 
acatalasemia type C showed a splicing mutation. In the Japanese acatalasemia II and the 
type A and B of Hungarian acatalasemia, deletion or insertion of nucleotides was observed 
in the coding regions, and a frame shift altered downstream amino acid sequences and 
formed truncated proteins. In the Hungarian acatalasemia D, substitution of an exon 
nucleotide was found. In mouse and beagle dog acatalasemia, substitution of nucleotides in 
the coding regions was also observed. Studies of residual catalase in Swiss mouse and 
beagle dog acatalasemia showed that aberrant catalase protein degrades more quickly than 
normal catalase in cells (Ogata et al., 2008). Japanese-type acatalasemia (Takarara disease) is 
characterized by the almost total loss of catalase activity in erythrocytes and is often 
associated with ulcerating oral lesions (Hirono et al, 1995). Polymerization of hemoglobin 
and aggregation of the acatalasemic erythrocytes observed upon the addition of hydrogen 
peroxide сan be the mechanism for the onset of Takarara disease (Masuoka et al., 2006). 
Catalase deficiency in Hungary has been reported to be associated with increased frequency 
of diabetes mellitus (Vitai et al, 2005). That is human acatalasemia may be a risk factor for 
the development of diabetes mellitus. Catalase plays a crucial role in the defense against 
oxidative-stress-mediated pancreatic beta cell death (Kikumoto et al., 2009). Exon 2 and 
neighboring introns of the catalase gene may be minor hot spots for type 2 diabetes mellitus 
susceptibility mutations (Vitai et al., 2005). The catalase gene was selected as a candidate 
gene because of the reduction of catalase enzyme activity and concomitant accumulation of 
excess hydrogen peroxide observed in the entire epidermis of vitiligo patients. One of three 
catalase genetic markers studied was found to be informative for genotypic analysis of 
Caucasian vitiligo patients and control subjects. Both case/control and family-based genetic 
association studies of the T/C single nucleotide polymorphism (SNP) in exon 9 of the 
catalase gene, which is detectable with the restriction endonuclease BstX I, suggest possible 
association between the catalase gene and vitiligo susceptibility. The observations that T/C 
heterozygotes are more frequent among vitiligo patients than controls and that the C allele 
is transmitted more frequently to patients than controls suggest that linked mutations in or 
near the catalase gene might contribute to a quantitative deficiency of catalase activity in the 
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epidermis and the accumulation of excess hydrogen peroxide (Casp et al., 2002). The 
increased plasma homocysteine and inherited catalase deficiency together could promote 
oxidative stress via hydrogen peroxide. The patients with inherited catalase deficiency are 
more sensitive to oxidative stress of hydrogen peroxide than the normocatalasemic family 
members (Góth et al., 2003). The normal activity of glutathione peroxidase could prevent the 
lysis of the erythrocytes in acatalasemic patients. In the presence of extremely high levels of 
hydrogen peroxide acute hemolysis may not be excluded; therefore, follow-up of these 
patients is required (Góth et al., 1995). Patients with low (inherited and acquired) catalase 
activities who are treated with infusion of uric acid oxidase because they are at risk of 
tumour lysis syndrome may experience very high concentrations of hydrogen peroxide. 
They may suffer from methemoglobinaemia and haemolytic anaemia which may be 
attributed either to deficiency of glucose-6-phosphate dehydrogenase or to other unknown 
circumstances. Data have not been reported from catalase deficient patients who were 
treated with uric acid oxidase. It may be hypothesized that their decreased blood catalase 
could lead to an  increased concentration of hydrogen peroxide which may cause 
haemolysis and formation of methemoglobin. Blood catalase activity should be measured 
for patients at risk of tumour lysis syndrome prior to uric acid oxidase treatment. (Góth et 
al., 2007). Acatalasic erythrocytes metabolized glucose through the hexosemonophosphate 
shunt at three times the normal rate and increased this rate many times when exposed to 
levels of peroxide-generating drugs that had negligible effect on normal erythrocytes. When 
erythrocytes lacked both their hexosemonophosphate shunt and catalase, oxidative damage 
was greater than with either deficiency alone (Harry Jacobt et al., 1965). Under acatalasemic 
conditions, it was suggested that NAD(P)H is an important factor to prevent oxidative 
degradation of hemoglobin (Masuoka et al., 2003). 
2.9 Point mutation in adenylate kinase and pyrimidine 5'-nucleotidase 
Erythrocytes adenylate kinase (AK) deficiency is a rare hereditary erythroenzymopathy 
associated with moderate to severe nonspherocytic hemolytic anemia and, in some cases, 
with mental retardation and psychomotor impairment. To date, diagnosis of AK deficiency 
depends on demonstration of low enzyme activity in erythrocytes and detection of 
mutations in AK1 gene. Five variants of AK1 isoenzyme-bearing mutations (118G→A, 
190G→A, 382C→T, 418-420del, and 491A→G) are found in AK-deficient patients with 
chronic hemolytic anemia (Abrusci et al., 2007). Pyrimidine 5' -nucleotidase (P5'N-1) 
deficiency is one of the frequent enzyme abnormalities causing hereditary nonspherocytic 
hemolytic anemia. The disease is transmitted as an autosomal recessive trait. The degree of 
hemolysis is generally mild-to moderate. The structural human gene for P5'N-1 is now 
available and fifteen different mutations have been identified so far. Some patients exhibit 
high residual P5'N-1 activity, suggesting that P5'N-1 deficiency is compensate by other 
nucleotidases and/or alternative pathways in nucleotide metabolism. No specific therapy 
for P5'N-1 deficiency is now available (Kondo, 1990; Chiarelli et al., 2006). 
3. Conclusion 
The optimum metabolism of erythrocytes depends on activity of glucose transporter type 1, 
glycolysis enzymes, glutathione synthetase, glutathione reductase, glutathione peroxidase, 
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peroxiredoxin 2, superoxide dismutase 1, catalase and  nucleotide metabolism. To date, all 
of the enzyme-deficient variants which have been investigated were caused by point 
mutations. Most mutations are located in the coding sequences of genes.  
Expression of mutant glucose transporter 1 (GLUT1) resulted in a significant decrease in 
transport activity. Impaired glucose transport across brain tissue barriers results in epilepsy, 
mental retardation and motor disorders. Recently, mutations in GLUT1 gene have been 
identified as a cause in some patients with autosomal dominant paroxysmal exercise-
induced dyskinesias,  which in certain cases was accompanied by hemolytic anemia with 
echinocytosis. The causative mutations for some forms of hereditary stomatocytosis have 
been found to result from mutations in SLC2A1, encoding GLUT1. Stomatocytosis is 
associated with a cold-induced cation leak, hemolytic anemia and hepatosplenomegaly but 
also with cataracts, seizures, mental retardation and movement disorder. 
Erythrocytes glucose metabolism only depends on hexokinase 1 (HK1) activity. HK1 
deficiency is a very rare disease with a clinical phenotype of hemolysis. Glucose-6-
phosphate isomerase (GPI) deficiency is one of the most common cause of congenital 
nonspherocytic hemolytic anemia. Patients with inherited GPI deficiency present with 
nonspherocytic anemia of variable severity, and with neuromuscular dysfunction. 
Homozygous GPI deficiency in human is responsible for chronic nonspherocytic hemolytic 
anemia. GPI deficiency can become clinically relevant consequence to the administration of 
drugs. GPI deficiency can lead to the impairment of the system that removes free radicals 
generated by amoxicillin, thereby resulting in oxidation of hemoglobin and destabilization 
of erythrocytes membranes, with acute hemolysis and severe hemoglobinuria. 
Phosphofructokinase (PFK) deficiency was the first recognized disorder that directly affects 
glycolysis. Several mutations in PFKM cause type VII glycogen storage disease (GSDVII), 
which is a rare disease described by Tarui (Tarui’s disease). GSDVII is characterized by the 
coexistence of muscle disease and hemolytic process. PFK deficiency include isolated 
hemolytic anemia, compensated hemolysis or asymptomatic state. Portal and mesenteric 
vein thrombosis in patient with a known case of PFK deficiency has been described. 
Aldolase A deficiency has been reported as a rare, autosomal recessive disorder. Clinical 
manifestations of aldolase A deficiency included transfusion-dependent anemia, increasing 
muscle weakness and rhabdomyolysis. Hemolytic crisis in patients with aldolase A 
deficiency can be provoked by fever, upper respiratory infections.  
Recent evidence suggests that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a 
multifunctional protein displaying diverse activities distinct from its conventional metabolic 
role. GAPDH has been referred to as a "housekeeping" protein and based on the view that 
GAPDH gene expression remains constant. Evidence of an impairment of GAPDH 
glycolytic function in Alzheimer's and Huntington's disease subcellular fractions despite 
unchanged gene expression is reported. 
Phosphoglycerate kinase (PGK) deficiency is generally associated with chronic hemolytic 
anemia, although it can be accompanied by either mental retardation or muscular disease.  
In human, phosphoglycerate mutase (PGAM) is present in three isozymes. The homodimer 
BB is present in erythrocytes. Only one PGAM BB deficiency has been reported. In a patient 
with clinical diagnosis of Hereditary Spherocytosis and partial deficiency (50%) of 
erythrocytes PGAM activity, a homozygous point mutation have recently been reported. 
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Erytrocytes enolase deficiency is rare, and its pathogenesis, inheritance and clinical 
manifestation have not been firmly established. Enolase deficiency causes chronic 
nonspecific hemolytic anemia. Chronic hemolytic anemia associated with erythrocyte 
enolase deficiency exacerbated by ingestion of nitrofurantoin has been described. 
Pyruvate kinase (PK) deficiency is one of the most frequent red cell enzymatic defect 
responsible for hereditary nonspherocytic hemolytic anemia. According to the most recent 
database, more than 180 mutations have been reported on the PK-LR gene. Erythrocytes PK 
plays an important role as an antioxidant during erythroid differentiation. Glycolytic 
inhibition by erythrocytes PK gene mutation augmented oxidative stress, leading to 
activation of hypoxia-inducible factor-1 as well as downstream proapoptotic gene 
expression. 
Glucose 6-phosphate dehydrogenase (G6PD) deficiency, the most common enzyme 
deficiency worldwide, causes a spectrum of diseases including neonatal hyperbilirubinemia, 
acute hemolysis, and chronic hemolysis. Persons with this condition also may be 
asymptomatic. Approximately 400 million people are affected worldwide ahd about 160 
mutations have been reported. Acute hemolysis is caused by exposure to an oxidative 
stressor such as infection, some foods (fava beans), drugs or various chemicals.  
Few cases of erytrocytes 6-phosphogluconate dehydrogenase (6PGD) deficiency in human 
have been described. The episodic hemolytic events with jaundice in patients with 6PGD 
deficiency may be the result of a defective erythrocytes ability to counteract conditions of 
marked oxidative stress as happens at birth and following traumatic events. 
Glutathione synthetase (GS) deficiency is a rare autosomal recessive disorder. Clinically 
affected patients present with severe metabolic acidosis, 5-oxoprolinuria, increased rate of 
hemolysis, hemolytic anemia, neonatal jaundice and defective function of the central 
nervous system. A milder form of GS deficiency apparently restricted to erythrocytes, is 
associated with decreased erythrocyte GSH levels and hemolytic disease, which is usually 
well compensated. Complete loss of function of both GS alleles is probably lethal. 
The clinical symptoms of glutathione reductase (GR) deficiency include reduced lifespan of 
erythrocytes, cataract, and favism (hemolytic crises after eating fava beans). GR deficiency may 
alter the clinical manifestation of an unstable hemoglobinopathy and may be the cause of 
neonatal hyperbilirubinemia. GR deficiency state can be asymptomatic as the residual enzyme 
activity might be sufficient to maintain the reduced glutathione level to prevent oxidative 
stress. Whereas inherited glutathione reductase deficiency is rare, acquired GR deficiency due 
to low amounts of riboflavin in the diet is common in malnourished populations. 
Severe acute hemoglobinemia and hemoglobinuria has been described as a result a hereditary 
heterozygous glutathione peroxidase (GPx) deficiency in Japan. Patients with reduced GPx 
activity are at a high risk of developing carbamazepine-induced hemolytic crisis and/or 
aplastic crisis. Point mutations in gene peroxiredoxin 2 in human are not described. 
Deficiency of the SOD1 gene causes anemia and autoimmune responses against 
erythrocytes. Severity of anemia and levels of intracellular reactive oxygen species are 
positively correlated. Oxidation-mediated autoantibody production may be a more general 
mechanism for autoimmune hemolytic anemia and related autoimmune diseases. Shift in 
glucose metabolism to the pentose phosphate pathway and decrease in the energy charge 
potential of erythrocytes, increase in reactive oxygen species due to SOD1 deficiency 
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accelerates erythrocytes destruction by affecting carbon metabolism and increase oxidative 
modification of lipids and proteins. The resulting oxidation products are antigenic and, 
consequently, trigger autoantibody production, leading to autoimmune responses. 
Acatalasemia, the inherited deficiency of catalase has been detected in 11 countries. 
Japanese-type acatalasemia (Takarara disease) is characterized by the almost total loss of 
catalase activity in erythrocytes and is often associated with ulcerating oral lesions. 
Polymerization of hemoglobin and aggregation of the acatalasemic erythrocytes observed 
upon the addition hydrogen peroxide сan be the mechanism for the onset of Takarara 
disease. The patients with inherited catalase deficiency are more sensitive to oxidative stress 
to hydrogen peroxide. In the presence of extremely high levels of hydrogen peroxide acute 
hemolysis may not be excluded. Patients with low inherited catalase activities who are 
treated with infusion of uric acid oxidase because they are at risk of tumour lysis syndrome 
may experience very high concentrations of hydrogen peroxide. Inherited adenylate kinase 
deficiency and pyrimidine 5'-nucleotidase deficiency causes hemolytic anemia. 
Under physiological conditions, changes in the activity of proteins and enzymes of 
erythrocytes owing to point mutations may not be appreciable, however under certain 
conditions for example, the neonatal period, activation of oxidative stress such as during 
nfection, a hypoxemia-ischemia, an acidosis, reception of some medicament, influence of 
toxins, point mutations in proteins and enzymes of erythrocytes can lead to premature 
destruction of erytrocytes, development of intravascular hemolysis and hemolytic anemia. 
Hence, erytrhrocyte enzyme deficiency should be considered in patients with hemolytic 
anaemia. Extended molecular analysis is useful for studying how several interacting gene 
mutations contribute to the clinical variability of erytrocytes enzymes deficiency. 
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